Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates

Current Osteoporosis Reports

Volumn 8, Issue 1, 2010, Pages 34-39

  Nieves, Jeri W ^a   Cosman, Felicia ^a  

^a HELEN HAYES HOSPITAL   (United States)

Author keywords

Bisphosphonate; Femoral; Fracture; Osteoporosis; Subtrochanteric

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

CLINICAL FEATURE; DISEASE ASSOCIATION; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HIP FRACTURE; INCIDENCE; LONG TERM CARE; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; STRESS FRACTURE;

AGE FACTORS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; TIME FACTORS;

EID: 77953611357     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0007-2     Document Type: Review

References (30)

1. Cosman F: Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 2009, 15:483-493.
2. Salminen S, Pihlajamaki H, Avikainen V, et al.: Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 1997, 43:117-122.
3. Butler JE, Brown SL, McConnell BG: Subtrochanteric stress fractures in runners. Am J Sports Med 1982, 10:228-232.
4. Mullaji AB, Thomas TL: Low-energy subtrochanteric fractures in elderly patients: results of fixation with the sliding screw plate. J Trauma 1993, 34:56-61.
5. Salminen ST, Pihlajamaki HK, Avikainen VJ, Bostman OM: Population-based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 2000:241-249.
6. Ekstrom W, Nemeth G, Samnegard E, et al.: Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients. Injury 2009, 40:371-376.
7. Goh SK, Yang KY, Koh JS, et al.: Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349-353.
8. Kwek EB, Goh SK, Koh JS, et al.: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008, 39:224-231.
9. Neviaser AS, Lane JM, Lenart BA, et al.: Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350. A total of 70 people (59 women, 11 men), all low-energy subtrochanteric and midshaft femur fractures admitted to a trauma center in New York over 5 years, were reviewed. Of the 25 women on alendronate, 19 were identified as having a specific radiographic pattern (simple transverse fracture with a unicortical beak within a background of cortical hypertrophy). The mean duration of alendronate use was longer in those who had the fracture pattern compared to those without the fracture pattern.
10. Odvina CV, Levy S, Rao S, et al.: Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009 Mar 19 [Epub ahead of print].
11. Visekruna M, Wilson D, McKiernan FE: Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948-2952.
12. Lee P, van der Wall H, Seibel MJ: Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007, 30:590-597.
13. Cheung RK, Leung KK, Lee KC, Chow TC: Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007, 13:485-489.
14. Demiralp B, Ilgan S, Ozgur Karacalioglu A, et al.: Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007, 127:597-601.
15. Somford MP, Draijer FW, Thomassen BJ, et al.: Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736-1740.
16. Armamento-Villareal R, Napoli N, Panwar V, Novack D: Suppressed bone turnover during alendronate therapy for highturnover osteoporosis. N Engl J Med 2006, 355:2048-2050.
17. Kumm DA, Rack C, Rutt J: Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty 1997, 12:580-583.
18. Schneider JP: Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006, 61:31-33.
19. Sayed-Noor AS, Sjoden GO: Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 2009, 467:1921-1926.
20. Husada G, Libbeerecht K, Peeters T, Populaire J: Bilateral middiaphyseal femoral stress fractures in the elderly. Eur J Trauma 2005, 35:68-71.
21. Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
22. Arlot M, Meunier PJ, Boivin G, et al.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.
23. Ing-Lorenzini K, Desmeules J, Plachta O, et al.: Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009, 32:775-785.
24. Capeci CM, Tejwani NC: Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009, 91:2556-2561.
25. Lenart BA, Neviaser AS, Lyman S, et al.: Association of lowenergy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362. This study attempts to determine the risk factors for low-energy femoral fractures compared with a control group of patients with classic osteoporosis-related hip fractures of the femoral neck and intertrochanteric region. Bisphosphonate use was observed in 15 of the 41 subtrochanteric and shaft cases, compared with nine of the 82 hip fracture control subjects (OR, 4.44; 95% CI, 1.77-11.35). Patients with subtrochanteric/shaft fractures cases were more likely to be on long-term bisphosphonates than those with intertrochanteric and femoral neck fractures.
26. Abrahamsen B, Eiken P, Eastell R: Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
27. ·· Nieves JW, Bilezikian JP, Lane JM, et al.: Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2009 May 30 [Epub ahead of print]. The overall incidence of subtrochanteric and shaft fractures combined was less than 30/100,000 person-years. Although this study could not look at the specific radiologic pattern discussed in the case series, the incidence estimates should provide an upper limit of the number of the specific fractures discussed here.
28. Mautalen CA, Vega EM, Einhorn TA: Are the etiologies of cervical and trochanteric hip fractures different? Bone 1996, 18(3 Suppl):133S-137S.
29. Ferris BD, Kennedy C, Bhamra M, Muirhead-Allwood W: Morphology of the femur in proximal femoral fractures. J Bone Joint Surg Br 1989, 71:475-477.
30. Wernecke G, Namduri S, Dicarlo EF, et al.: Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J 2008, 4:123-127.